The update on the rationale, use and selection of β-blockers in heart failure

Purpose of review: The purpose of this review was to describe important developments in the selection of β-blockers in heart failure. Recent findings: The superiority of carvedilol over metoprolol tartrate in one clinical trial is demonstrated, and multiple studies investigated the potential mechanisms of benefit. Current practice patterns still demonstrate the importance of understanding barriers to the effective use of beta-blocking agents. Symmary: There are continued refinements in the choice of β-blockers in heart failure, but clearly an important remaining challenge is to modify health care delivery in an effort to maximize adherence to guidelines.